Vatelizumab

Vatelizumab: An Investigational Integrin Alpha 2 Immunomodulator

Vatelizumab is an experimental immunomodulator that targets and binds to integrin alpha 2, a cell adhesion molecule involved in various cellular processes including inflammation, vascularization, and tissue repair.

Mechanism of Action

Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits. The specific target of Vatelizumab, integrin alpha 2, is predominantly expressed on platelets and certain leukocyte subsets and is implicated in cell-cell and cell-matrix interactions<ref>Shattil SJ, Kim C, Ginsberg MH. (2010). The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol. 11(4):288-300.</ref>. By binding to this integrin, Vatelizumab potentially modulates inflammatory processes, making it a candidate for treating inflammatory disorders like inflammatory bowel disease (IBD).

Clinical Evaluation

Following promising preclinical studies, Vatelizumab advanced to clinical trials. The primary aim was to evaluate its therapeutic potential, particularly in:

• Inflammatory Bowel Disease (IBD): An umbrella term for chronic inflammatory conditions of the gastrointestinal tract, including Crohn's disease and ulcerative colitis.

However, during Phase II trials, Vatelizumab did not demonstrate sufficient efficacy in ameliorating the symptoms or pathology of IBD. Due to this lack of observed therapeutic benefit, the drug was withdrawn from these trials<ref>Research Update, [Pharmaceutical Company Name], Phase II Trials Report, [Year of Withdrawal].</ref>.

Implications and Future Perspectives

The withdrawal of Vatelizumab from Phase II trials underscores the complexities involved in drug development, particularly for multifactorial conditions like IBD. Even though a therapeutic agent may show promise during preclinical evaluations, human trials may reveal limitations due to varied factors, such as metabolism, bioavailability, or even off-target effects.

While Vatelizumab's journey in IBD therapy was halted, the knowledge gained from its development and clinical assessment provides valuable insights that can guide future research efforts in this domain. For instance:

• Further exploration into integrin biology could identify new potential therapeutic targets.
• The data obtained from the Vatelizumab trials might be repurposed to improve drug design or treatment strategies for other inflammatory conditions.

Conclusion

Vatelizumab represents one of the many investigational compounds in the evolving landscape of immunomodulatory drug research. Its journey, from conception to clinical trials, provides crucial lessons on the challenges and intricacies of drug development for complex conditions like IBD.

References

<references />

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia